NCT06333678 - A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Durvalumab

10 mg/kg IV every 2 weeks or 1500 mg/kg IV every 4 weeks for up to 12 months.

DRUG

Sotorasib

960 mg, Patients who do not tolerate sotorasib at 960 mg can be dose reduced to 120 mg.

Trial Locations (11)

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack

Lehigh Valley Health Network (Data Collection Only), Allentown

University of Miami (Data Collection Only), Miami

Vanderbilt University (Data Collection Only), Nashville

University of Michigan (Data Collection Only), Ann Arbor

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale